share_log

Canaccord Genuity Maintains Hold on Sage Therapeutics, Lowers Price Target to $17

Benzinga ·  Apr 26 08:56

Canaccord Genuity analyst Sumant Kulkarni maintains Sage Therapeutics (NASDAQ:SAGE) with a Hold and lowers the price target from $21 to $17.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment